Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Clinical Oncology

Volumn 28, Issue 12, 2016, Pages e199-e205

  Yap, M L ^a,b   Sun, A ^a,b   Higgins, J ^a,b   Clarke, K ^a,b   Marshall, A ^a,b   Becker, N ^a,b   Le, L W ^a   Vines, D C ^a,b   Bezjak, A ^a,b   Bissonnette, J P ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adaptive radiotherapy; dose escalation; four dimensional PET CT; intensity modulated radiotherapy; lung cancer; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MALE; MAXIMUM PERMISSIBLE DOSE; NON SMALL CELL LUNG CANCER; ORGANS AT RISK; PET-CT SCANNER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; RESPIRATORY GATED IMAGING; SQUAMOUS CELL LUNG CARCINOMA; THORAX RADIOGRAPHY; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONFORMAL RADIOTHERAPY; LUNG NEOPLASMS; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FLUORODEOXYGLUCOSE F18; FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY; HUMANS; LUNG NEOPLASMS; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84994807546     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.08.011     Document Type: Article

References (23)

1. [1] Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013, International Agency for Research on Cancer, Lyon, France Available at: http://globocan.iarc.fr (accessed 14 May 2014).
2. [2] Auperin, A., Le Pechoux, C., Rolland, E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
3. [3] Bradley, J.D., Paulus, R., Komaki, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:2 (2015), 187–199.
4. [4] Aerts, H.J., Bussink, J., Oyen, W.J., et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 75:1 (2012), 73–76.
5. [5] Bissonnette, J.P., Purdie, T.G., Higgins, J.A., Li, W., Bezjak, A., Cone-beam computed tomographic image guidance for lung cancer radiation therapy. Int J Radiat Oncol Biol Phys 73 (2009), 927–934.
6. [6] Spoelstra, F.O., Pantarotto, J.R., van Sornsen de Koste, J.R., et al. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys 75:4 (2009), 1092–1097.
7. [7] Bentzen, S.M., Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6:2 (2005), 112–117.
8. [8] Bradley, J., Bae, K., Choi, N., et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys 82:1 (2012), 435–441.
9. [9] Nehmeh, S.A., Erdi, Y.E., Pan, T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31:12 (2004), 3179–3186.
10. [10] Vines, D.C., Keller, H., Hoisak, J.D., et al. Quantitative PET comparing gated with nongated acquisitions using a NEMA phantom with respiratory-simulated motion. J Nucl Med Technol 35:4 (2007), 246–251.
11. [11] Aristophanous, M., Berbeco, R.I., Killoran, J.H., et al. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys 82:1 (2012), e99–e105.
12. [12] Biehl, K.J., Kong, F.M., Dehdashti, F., et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?. J Nucl Med 47:11 (2006), 1808–1812.
13. [13] Wu, K., Ung, Y.C., Hornby, J., et al. PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?. Int J Radiat Oncol Biol Phys 77:3 (2010), 699–706.
14. [14] Mah, K., Caldwell, C.B., Ung, Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52:2 (2002), 339–350.
15. [15] van Baardwijk, A., Bosmans, G., Boersma, L., et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 68:3 (2007), 771–778.
16. [16] van Elmpt, W., De Ruysscher, D., van der Salm, A., et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 104:1 (2012), 67–71.
17. [17] Moller, D.S., Khalil, A.A., Knap, M.M., et al. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients. Acta Oncol 50:6 (2011), 883–888.
18. [18] Feng, M., Kong, F.M., Gross, M., et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 73:4 (2009), 1228–1234.
19. [19] Gillham, C., Zips, D., Ponisch, F., et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol 88:3 (2008), 335–341.
20. [20] Matuzsak, M.M., Xiao, Y., Presley, J., et al. The importance of dry run credentialing for RTOG 1106/ACRIN 6697: a trial of individualized adaptive radiation therapy for patients with locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 83:Suppl. 3 (2012), S26–S27.
21. [21] Ball, D.L., Fisher, R.J., Burmeister, B.H., et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 106:3 (2013), 305–311.
22. [22] Bissonnette, J.P., Medlam, G., Trend analysis of radiation therapy incidents over seven years. Radiother Oncol 96:1 (2010), 139–144.
23. [23] Mehmood, Q., Sun, A., Becker, N., et al. Predicting radiation esophagitis using 18F-FDG PET during chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 11:2 (2016 Feb 1), 213–221.